alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 107th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 600 Engrossed in House (EH)]

                 In the House of Representatives, U.S.,

                                                     November 13, 2002.
    Resolved, That upon the adoption of this resolution it shall be in order 
without intervention of any point of order to consider in the House the bill 
(H.R. 5710) to establish the Department of Homeland Security, and for other 
purposes. The bill shall be considered as read for amendment. The amendment 
specified in section 2 of this resolution shall be considered as adopted. The 
previous question shall be considered as ordered on the bill, as amended, to 
final passage without intervening motion except: (1) one hour of debate on the 
bill, as amended, equally divided and controlled by the chairman and ranking 
minority member of the Select Committee on Homeland Security; and (2) one motion 
to recommit with or without instructions.
    Sec. 2. The amendment referred to in the first section of this resolution is 
as follows:
            Amend section 2(10)(B) so as to read:
                    ``(B) an Indian Tribe or authorized tribal organization, or 
                in Alaska a Native Village or Alaska Regional Native 
                Corporation; and''.
            Attest:

                                                                          Clerk.
```
1

Troutman, Jake (FAA)

From: Troutman, Jake (FAA)

Sent: Friday, June 12, 2015 4:29 PM

To: 'ralphboddicker@gmail.com'

Cc: Pappas, Rob (FAA)

Subject: Request for Additional Information - Ralph J. Boddicker

Dear Mr. Boddicker:  

This letter is to inform you that the following information is missing from your petition (Docket No. FAA‐2015‐

1119).  This information is necessary for the Federal Aviation Administration (FAA) to process your petition.  

* Describe the aircraft make(s), model(s), and type(s)(i.e. ‐ fixed‐wing,rotorcraft, lighter‐than‐air) for the proposed UAS

operation.  The description(s) should include the maximum weight (including payload).  This information can be located

in the aircraft manual(s).  

Please submit the additional information (non‐proprietary) to your docket at www.regulations.gov and submit any

proprietary information to the FAA Headquarters or electronically via e‐mail to 333exemptions@faa.gov.  If you want us

to process your request any further, we must receive the information described above by 6/29/2015.  If we do not

receive the information, we will close the docket without notifying you further.  

If you have any questions, please feel free to contact me at (202) 267‐9521.  

Sincerely,

Jake J Troutman

Program Analyst | Rulemaking

FAA Office of Aviation Safety

Airmen and Airspace Rules Division

202‐267‐9521
Docket: HHS-OS-2010-0015 

Group Health Plans and Health Insurance Coverage: Interim Final Rules for Relating to Status as 

a Grandfathered Health Plan under the Patient Protection and Affordable Care Act 

Comment On: HHS-OS-2010-0015-0001 

Group Health Plans and Health Insurance Coverage: Interim Final Rules for Relating to Status as 

a Grandfathered Health Plan under the Patient Protection and Affordable Care Act 

Document: HHS-OS-2010-0015-0007 

Comment on FR Doc # 2010-14488 

Submitter Information 

Name: Kathy Dupree 

Organization: Core Laboratories 

General Comment 

The Agencies have requested comments on on how network and drug formulary changes should 

be treated and whether they constitute a signficiant plan change. I offer comments as the 

administrator of a Self Funded Plan. Changes in a network are usually done so that Plan 

Participants have the advantage of a wide choice of providers in their geographic area. New 

network may offer financially advantageous discounts to both the Participants and the Plan. This 

is an effective way of "bending the cost curve" without increasing out-of-pocket. It is important to 

note that networks can be changed without changing carriers. 

For example, one proposed change in network increased provider penetration nationwide, 

increased network discounts almost 5% and is projected to save a health plan almost $1M in three 

years. It is a significant change but one with no adverse affects on the Participants. 

Modifying a drug forumulary can also "bend the cost curve" while affecting only those members 

who use the drugs involved in the modification. Typically, forumularies are modified to make 

them consistent with FDA guidelines in the use of prescription drugs. It may involve moving tiers 

or disallowing drugs not proven effective or for which there are multiple other alternatives. This is 

not a significant change but a evolutionary process that addresses the ongoing changes in 

medicine. 

PUBLIC SUBMISSION 

As of: August 12, 2010 

Received: June 28, 2010 

Status: Posted 

Posted: July 23, 2010 

Tracking No. 80b0c1a4 

Comments Due: August 16, 2010

Submission Type: Web

Page 1 of 1

https://fdms.erulemaking.net/fdms-web-agency/ContentViewer?objectId=0900006480b0c1... 8/12/2010
[Federal Register Volume 88, Number 163 (Thursday, August 24, 2023)]
[Notices]
[Page 57969]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18219]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE


Statement of Claim for Filing of Claims in the Guam Claims 
Program Pursuant to the Guam World War II Loyalty Recognition Act; 
Correction

AGENCY: Foreign Claims Settlement Commission, Department of Justice.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Foreign Claims Settlement Commission, Department of 
Justice (DOJ), published a document in the Federal Register of August 
1, 2023, concerning request for comments on the Statement of Claim for 
filing of Claims in the Guam Claims Program Pursuant to the Guam World 
War II Loyalty Recognition Act.

DATES: Submit comments on the Statement of Claim for filing of Claims 
in the Guam Claims Program Pursuant to the Guam World War II Loyalty 
Recognition Act before October 2, 2023.

FOR FURTHER INFORMATION CONTACT: Jeremy LaFrancois, 202-616-6981.

SUPPLEMENTARY INFORMATION:

Correction

    In the Federal Register of August 1, 2023, in FR Doc. 2023-16291, 
on page 50174, third column, in the AGENCY and SUMMARY captions, 
correct the agency name to read: Foreign Claims Settlement Commission.

    Dated: August 17, 2023.
Darwin Arceo,
Department Clearance Officer for PRA, U.S. Department of Justice.
[FR Doc. 2023-18219 Filed 8-23-23; 8:45 am]
BILLING CODE 4410-18-P
**EXHIBIT 23.4****INDEPENDENT AUDITORS’ CONSENT**The Board of DirectorsCT Communications, Inc.:     We consent to incorporation by reference in the RegistrationStatements (Registration Nos. 33-59641, 33-59645, 333-15537,333-38895, 333-65818, 333-119873 and 333-65846) of CTCommunications, Inc. of our report dated February 23, 2005,relating to the audited consolidated balance sheet of PalmettoMobileNet, L.P. as of December 31, 2004 and the relatedconsolidated statements of income and partners’ equity, andcash flows for the year ended December 31, 2004, whichreport is included in the December 31, 2004 Annual Reporton Form 10-K of CT Communications, Inc.     /s/ Elliott Davis, LLCColumbia, South CarolinaMarch 29, 2005
# Euroopan unionin C 152/9. k

| | ISSN 1725-2490 |
| --- | --- |
| Euroopan unionin
  virallinen lehti | C 152 |
| | |
| Suomenkielinen laitos | Tiedonantoja ja ilmoituksia | 47. vuosikerta9. kesäkuu 2004 |

ISSN 1725-2490

Euroopan unionin

virallinen lehti

C 152

Suomenkielinen laitos

Tiedonantoja ja ilmoituksia

47. vuosikerta9. kesäkuu 2004

---

| Ilmoitusnumero | Sisältö | Sivu |
| --- | --- | --- |
| | I   Tiedonantoja |
| | Komissio |
| 2004/C 152/1 | Euron kurssi | 1 |

Ilmoitusnumero

Sisältö

Sivu

I   Tiedonantoja

Komissio

2004/C 152/1

Euron kurssi

1

| FI | |
| --- | --- |

FI

---

I Tiedonantoja

Komissio

| 9.6.2004 | FI | Euroopan unionin virallinen lehti | C 152/1 |
| --- | --- | --- | --- |

9.6.2004

FI

Euroopan unionin virallinen lehti

C 152/1

---

Euron kurssi (1)

8. kesäkuuta 2004

(2004/C 152/01)

1 euro=

| | Rahayksikkö | Kurssi |
| --- | --- | --- |
| USD | Yhdysvaltain dollaria | 1,2294 |
| JPY | Japanin jeniä | 135,08 |
| DKK | Tanskan kruunua | 7,4349 |
| GBP | Englannin puntaa | 0,66840 |
| SEK | Ruotsin kruunua | 9,1040 |
| CHF | Sveitsin frangia | 1,5229 |
| ISK | Islannin kruunua | 87,36 |
| NOK | Norjan kruunua | 8,1885 |
| BGN | Bulgarian leviä | 1,9558 |
| CYP | Kyproksen puntaa | 0,58300 |
| CZK | Tšekin korunaa | 31,243 |
| EEK | Viron kruunua | 15,6466 |
| HUF | Unkarin korinttia | 251,15 |
| LTL | Liettuan litiä | 3,4527 |
| LVL | Latvian latia | 0,6623 |
| MTL | Maltan liiraa | 0,4263 |
| PLN | Puolan zlotya | 4,5957 |
| ROL | Romanian leuta | 40 758 |
| SIT | Slovenian tolaria | 239,1500 |
| SKK | Slovakian korunaa | 39,870 |
| TRL | Turkin liiraa | 1 811 841 |
| AUD | Australian dollaria | 1,7507 |
| CAD | Kanadan dollaria | 1,6520 |
| HKD | Hongkongin dollaria | 9,5838 |
| NZD | Uuden-Seelannin dollaria | 1,9568 |
| SGD | Singaporin dollaria | 2,0990 |
| KRW | Etelä-Korean wonia | 1 423,46 |
| ZAR | Etelä-Afrikan randia | 8,0262 |

Rahayksikkö

Kurssi

USD

Yhdysvaltain dollaria

1,2294

JPY

Japanin jeniä

135,08

DKK

Tanskan kruunua

7,4349

GBP

Englannin puntaa

0,66840

SEK

Ruotsin kruunua

9,1040

CHF

Sveitsin frangia

1,5229

ISK

Islannin kruunua

87,36

NOK

Norjan kruunua

8,1885

BGN

Bulgarian leviä

1,9558

CYP

Kyproksen puntaa

0,58300

CZK

Tšekin korunaa

31,243

EEK

Viron kruunua

15,6466

HUF

Unkarin korinttia

251,15

LTL

Liettuan litiä

3,4527

LVL

Latvian latia

0,6623

MTL

Maltan liiraa

0,4263

PLN

Puolan zlotya

4,5957

ROL

Romanian leuta

40 758

SIT

Slovenian tolaria

239,1500

SKK

Slovakian korunaa

39,870

TRL

Turkin liiraa

1 811 841

AUD

Australian dollaria

1,7507

CAD

Kanadan dollaria

1,6520

HKD

Hongkongin dollaria

9,5838

NZD

Uuden-Seelannin dollaria

1,9568

SGD

Singaporin dollaria

2,0990

KRW

Etelä-Korean wonia

1 423,46

ZAR

Etelä-Afrikan randia

8,0262

---

(1)

Lähde: Euroopan keskuspankin ilmoittama viitekurssi.

---
Essex County Court of Special Sessions.

#### STATE OF NEW JERSEY, PLAINTIFF-APPELLEE, v. HARRY KNOWLES, DEFENDANT-APPELLANT.

Decided November 15, 1933.

For the plaintiff-appellee, *William A. Wachenfeli*(by *Leon W. Kapp,*prosecutor of the pleas).

For the defendant-appellant, *Howe & Davis.*

Hartshobne, J.

This is an appeal from a conviction of drunken driving under section 14, subdivision 3 of the Motor Vehicle act. *Pamph. L.*1921, *p.*643. The defendant rests his appeal solely on technical objections to the record below, having refused both at the trial below and at that here, to enter a defense on the merits, in order to obviate the possible waiver of his technical defenses under the rule laid down in *State*v. *Rosenblum,*102 *N. J. L.*125; 130 *Atl. Rep.*614.

The alleged offense occurred May 14th, 1933, subsequent to the enactment of the supplement to the Motor Vehicle act. *Pamph. L.*1933, *ch.*27, *p.*200. This enactment radically changes the entire appellate procedure under the Motor Vehicle act, and a concurrent enactment *(Pamph. L.*1933, *ch.*96, *p.*198) similarly alters the appellate procedure under the Traffic act. In the first place, the previous appellate jurisdiction of the Common Pleas is transferred in its entirety to the Court of Special Sessions. In the second place, the act provides that:

*914“Such appeal shall not operate to bring up the proceedings in the court appealed from for review, but shall operate as an application for a trial *de novo*and as a consent that said Court of Special Sessions may, during or before the trial, amend the complaint by making the charge more specific, definite, or certain, or in any other manner, including the substitution of any charge growing out of the same transaction or surrounding circumstances of which the tribunal appealed from had jurisdiction.”

The act further provides that such appeal shall operate as a waiver of time limitation provisions, but that, if a new charge is made, the court shall give the defendant opportunity to defend. These last provisions are, evidently, upon the theory that there is no constitutional right to appeal *(Reetz*v. Michigan, 188 *U. S.*508; *Lott*v. Pittman, 243 *Id.*588), so that the legislature can grant same upon such conditions as it sees fit, even to include the institution of new proceedings upon reasonable terms.

The new statute clearly evidences the further legislative intent that none of the record below is to be reviewed on the Special Sessions appeal, the proceedings to be considered substantially as if begun anew. In other words, the legislature has wiped out the previous right of the convicted defendant to have technical objections considered, either on appeal to the Common Pleas or on *certiorari*to the Supreme Court, and has now confined him to certiorari, if he desires his technical objections to proceedings in the court below to be considered.

Such being the clear legislative intent of the act, adopted prior to the commission of the ofíense here involved, and the appeal being based solely upon such technical objections, the defendant’s conviction is affirmed, and judgment may be entered accordingly.
Alpharma Inc.

                 Subsidiaries of the Registrant

                                                       EXHIBIT 21


NAME                               JURISDICTION WHICH
                                        ORGANIZED

United States:

Alpharma NW Inc.                        Washington
Alpharma U.S. Inc.                      Delaware
Barre Parent Corporation                Delaware
Alpharma USPD Inc.                      Maryland
G. F. Reilly Company                    Delaware
ParMed Pharmaceuticals, Inc.            Delaware
Alpharma Animal Health Company          Texas

Foreign:

A.L-Pharma A/S                          Denmark
Alpharma AS                             Norway
Allabinc de Mexico, S.A. de C.V.        Mexico
Empressa Laboratories De
   Mexico S.A. de C.V.                  Mexico
Dumex-Alpharma A/S                      Denmark
Dumex AG                                Switzerland
Dumex B.V.                              Holland
Dumex-Alpharma AB                       Sweden
Dumex Limited                           United Kingdom
Oy Dumex-Alpharma AB                    Finland
PT Dumex-Alpharma Indonesia             Indonesia
Alpharma do Brazil LTDA                 Brazil
Alpharma SARL                           France
Arthur H. Cox & Co. Limited             United Kingdom
Alpharma Fine Chemicals, Kft.           Hungary
Vetrepharm Ltd.                         United Kingdom
Alpharma Animal Health Pty. Ltd.        Australia
Jumer Laboratories                      France
Isis Pharma GmbH                        Germany
Isis Puren GmbH & Co. KG                Germany
Alpharma Belgium SPRL                   Belgium
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                           5,917
<SECURITIES>                                    23,030
<RECEIVABLES>                                   21,225
<ALLOWANCES>                                     1,145
<INVENTORY>                                      2,619
<CURRENT-ASSETS>                                54,062
<PP&E>                                           5,720
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  59,934
<CURRENT-LIABILITIES>                           20,070
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            69
<OTHER-SE>                                      39,795
<TOTAL-LIABILITY-AND-EQUITY>                    59,934
<SALES>                                         20,372
<TOTAL-REVENUES>                                20,372
<CGS>                                            7,547
<TOTAL-COSTS>                                    7,547
<OTHER-EXPENSES>                                 9,117
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  3,981
<INCOME-TAX>                                     1,433
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,548
<EPS-PRIMARY>                                      .17
<EPS-DILUTED>                                      .16
        

</TABLE>
---

Exhibit 31.2

CERTIFICATION PURSUANT TO
  SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Garry L. Anselmo, Chief Financial Officer of Silverado Gold
  Mines Ltd. (the "registrant"), certify that:

1. I have reviewed this annual report on Form 10-KSB of the registrant;

2. Based on my knowledge, this quarterly report does not contain
  any untrue statement of a material fact or omit to state a material fact necessary
  to make the statements made, in light of the circumstances under which such
  statements were made, not misleading with respect to the period covered by this
  quarterly report;

3. Based on my knowledge, the financial statements, and other
  financial information included in this quarterly report, fairly present in all
  material respects the financial condition, results of operations and cash flows
  of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible
  for establishing and maintaining disclosure controls and procedures (as defined
  in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls
  and procedures to ensure that material information relating to the registrant,
  including its consolidated subsidiaries, is made known to us by others within
  those entities, particularly during the period in which this quarterly report
  is being prepared;

b) evaluated the effectiveness of the
  registrant's disclosure controls and procedures as of a date within 90 days
  prior to the filing date of this quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report
  our conclusions about the effectiveness of the disclosure controls and procedures
  based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed,
  based on our most recent evaluation, to the registrant's auditors and the audit
  committee of registrant's board of directors (or persons performing the equivalent
  function):

a) all significant deficiencies in the
  design or operation of internal controls which could adversely affect the registrant's
  ability to record, process, summarize and report financial data and have identified
  for the registrant's auditors any material weaknesses in internal controls;
  and

b) any fraud, whether or not material,
  that involves management or other employees who have a significant role in the
  registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated
  in this quarterly report whether or not there were significant changes in internal
  controls or in other factors that could significantly affect internal controls
  subsequent to the date of our most recent evaluation, including any corrective
  actions with regard to significant deficiencies and material weaknesses.

Date: March 15, 2007

|By: /s/ Garry L. Anselmo
|------------------------
|Garry L. Anselmo,       
|Chief Financial Officer 



---
§ 604.19 Processing of advisory opinions. ( a ) A request for an advisory opinion shall be sent to the Chief Counsel at *ombudsman.charterservice@dot.gov*, and filed electronically in the Charter Service Advisory Opinion/Cease and Desist Order docket number FTA-2007-0023 at *http://www.regulations.gov* or sent to the dockets office located at 1200 New Jersey Ave., SE., West Building Ground Floor, Room W12-140, Washington, DC 20590, for submission to that docket.
( b ) The Chief Counsel shall make every effort to respond to a request for an advisory opinion within ten days of receipt of a request that complies with § 604.18(b). The Chief Counsel shall send his or her decision to the interested party, the docket, and the recipient, if appropriate.
CERTIFICATION PURSUANT TO 
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Annual Report of Alpharma Inc. (the "Company") on Form 10-K for the period ended December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:



(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



Dated:   March 1, 2007



/s/ Dean J Mitchell
Dean J. Mitchell

Chief Executive Officer

Dated:  March 1, 2007



/s/ Jeffrey S. Campbell

Jefrey S. Campbell
Interim Chief Financial Officer
EXHIBIT 11
                                                                      ----------






          STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS (LOSS)
                        DECEMBER 31, 2002, 2001 AND 2000




<TABLE><CAPTION>
                                                             2002             2001             2000
                                                         ------------     ------------     ------------
<S>                                                      <C>              <C>              <C>
NET EARNINGS (LOSS) PER COMMON SHARE - (BASIC)

Net income (loss)                                        $  2,236,651     $ (2,162,992)    $   (800,270)
                                                         ============     ============     ============

Weighted average number of common shares outstanding        6,755,660        6,690,933        6,628,667
                                                         ============     ============     ============

Net earnings (loss) per common share                     $       0.33     $      (0.32)    $      (0.12)
                                                         ============     ============     ============


NET EARNINGS (LOSS) PER COMMON SHARE - (DILUTED)

Net income (loss)                                        $  2,236,651     $ (2,162,992)    $   (800,270)
                                                         ============     ============     ============

Weighted average number of common shares outstanding        6,755,660        6,690,933        6,628,667

Add net additional common shares upon exercise of
  common stock options                                         92,288               --               --
                                                         ------------     ------------     ------------

Adjusted average common shares outstanding                  6,847,948        6,690,933        6,628,667
                                                         ============     ============     ============

Net earnings (loss) per common share                     $       0.33     $      (0.32)    $      (0.12)
                                                         ============     ============     ============
</TABLE>